Latest Safety News

Immutep’s novel immunotherapy combination with KEYTRUDA and chemotherapy shows promising response rates in first line non-small cell lung cancer, especially in patients with low or no PD-L1 expression.

Immutep Limited’s Phase II trial of eftilagimod alfa combined with radiotherapy and KEYTRUDA in soft tissue sarcoma patients has exceeded its primary endpoint, showing a 51.5% median tumor hyalinization rate, more than triple the historical standard. These promising results, presented at ESMO 2025, suggest a potential breakthrough in a challenging cancer indication.

Saunders International has landed a $19.8 million contract to build 11 tanks at a gold processing facility, reinforcing its foothold in the resources sector and promising revenue growth over the next two years.

Etherstack's subsidiary has won a significant £14.2 million contract to supply critical software for the UK's Emergency Services Network, marking a major milestone in mission-critical communications.

Perpetual Resources has launched a systematic exploration program across its key lithium projects in Brazil, aiming to expand on recent high-grade discoveries and define new drill targets.

RemSense Technologies has landed a pilot project with the Australian Gas Infrastructure Group to deploy its cutting-edge virtualplant platform, marking a key step into Australia’s gas transmission sector.

Alcidion Group Limited has reported a record FY25 with strong revenue growth, major NHS contract wins, and expanded AI capabilities in its Miya Precision platform, setting the stage for global healthcare IT expansion.

IMDEX Limited reported a resilient FY25 with steady margins, reduced net debt, and strategic acquisitions positioning it for growth. The company’s FY26 outlook is optimistic, supported by improving global exploration activity and technology adoption.

Health Canada has requested additional information, extending its review of CLINUVEL’s SCENESSE® for erythropoietic protoporphyria (EPP) into 2026. Meanwhile, Canadian patients continue to access the treatment via a Special Access Program.

Anteris Technologies has secured its first European regulatory clearance to commence the global PARADIGM Trial for its DurAVR Transcatheter Heart Valve, marking a significant step toward worldwide commercialization.

Santos Limited reported robust Q3 2025 results, highlighted by the Barossa LNG project commencing production and Pikka phase 1 nearing first oil. The company’s diversified portfolio and operational discipline underpin a confident outlook despite some operational delays.

TrivarX Limited has announced the acquisition of Stabl-Im, a novel stable isotope MRI technology for early brain tumor detection, backed by a $4.2 million capital raise including investment from biotech leader Dr Daniel Tillett.